CAST
Cardiac Arrhythmia Suppression Trial

Purpose To determine whether the suppression of asymptomatic or mildly symptomatic ventricular arrhythmias after myocardial infarction (MI) reduces the mortality rate in arrhythmia References The CAST investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321:406–412. Epstein AE, Bigger JT Jr, Wyse DG, et al: Events in the cardiac arrhythmia suppression trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol 1991, 18:14–19. Wyse DG, Hallstrom A, McBride R, et al: Events in the cardiac arrhythmia suppression trial (CAST): mortality in patients surviving open label titration but not randomised to double-blind therapy. J Am Coll Cardiol 1991, 18:20–28. Anderson JL, Platia EV, Hallstrom A, et al: Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 1994, 90:2843–2852. Goldstein S, Brooks MM, Ledingham R, et al: Association between ease of suppression of ventricular arrhythmia and survival. Circulation 1995, 91:79–83.

Apoio: Farmacêutica